Gilead Sciences reports almost US$900m in Q3 remdesivir sales
[NEW YORK] Remdesivir, a therapeutic to treat Covid-19, boosted third-quarter sales for pharma company Gilead Sciences by nearly US$900 million, according to results released Wednesday by the drugmaker.
The medication, sold under the brand name Veklury, which was originally developed to treat Ebola, has been shown to shorten the recovery time for patients hospitalized with the coronavirus. Gilead reported a 17 per cent jump in third-quarter revenues to US$6.6 billion.
AFP
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share